In this project we will explore highly innovative planning and delivery strategies to optimally utilize the powerful dose shaping capabilities of IMPT. The theoretical advantage of proton therapy compared to photon therapy is due to the reduced integral dose (dose bath) and the finite range. The added potential of IMPT compared to IMRT derives from the additional degree of freedom, i.e. the beamlet energy. However, to realize the true potential of IMPT, considerable further research is needed.
The specific aims of this project focus on different aspects that influence the power of IMPT: Robust optimization of the dose distributions to reduce their sensitivity to uncertainties, biological dose optimization, personalized treatment optimization, and finally, hypofractionation facilitated via the reduced dose bath achievable with IMPT. This project supports the mission of the NCI to improve the treatment and continuing care of cancer patients.

Public Health Relevance

This research aims to improve radiation treatment for cancer patients by improving our ability to direct the radiation at the tumor to spare adjacent normal tissue by using protons (charged particles) with intensity-modulated proton therapy. This can potentially improve cancer cure rates, reduce side effects, or both, depending on the clinical scenario. With an increasing number of proton centers in the United States and abroad, the research in this program project is increasingly important for public health.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA021239-37
Application #
9127126
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
37
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
Paganetti, Harald (2018) Proton Relative Biological Effectiveness - Uncertainties and Opportunities. Int J Part Ther 5:2-14
Jeter, Melenda D; Gomez, Daniel; Nguyen, Quynh-Nhu et al. (2018) Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A P Int J Radiat Oncol Biol Phys 100:730-737
Frank, Steven J; Blanchard, Pierre; Lee, J Jack et al. (2018) Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Semin Radiat Oncol 28:108-113
Yue, Jinbo; Shi, Qiuling; Xu, Ting et al. (2018) Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27:1563-1570
Botas, Pablo; Grassberger, Clemens; Sharp, Gregory et al. (2018) Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors. Phys Med Biol 63:035023
Guan, Fada; Geng, Changran; Ma, Duo et al. (2018) RBE Model-Based Biological Dose Optimization for Proton Radiobiology Studies. Int J Part Ther 5:160-171
Liao, Zhongxing; Simone 2nd, Charles B (2018) Particle therapy in non-small cell lung cancer. Transl Lung Cancer Res 7:141-152
Blanchard, Pierre; Gunn, Gary Brandon; Lin, Alexander et al. (2018) Proton Therapy for Head and Neck Cancers. Semin Radiat Oncol 28:53-63
Chen, Yizheng; Grassberger, Clemens; Li, Junli et al. (2018) Impact of potentially variable RBE in liver proton therapy. Phys Med Biol 63:195001
Geng, Changran; Gates, Drake; Bronk, Lawrence et al. (2018) Physical parameter optimization scheme for radiobiological studies of charged particle therapy. Phys Med 51:13-21

Showing the most recent 10 out of 47 publications